RAGE

RAGE

RAGE 詳細

Molecule Name
Advanced glycosylation end product-specific receptor
分子の別称
AGER,RAGE
Drug Development Progress
治験薬の数3
市販薬剤の数0
研究&開発段階Phase 3 Clinical
ターゲットの別称
Receptor for advanced glycosylation end products,AGER,Advanced Glycosylation End-Product Specific Receptor,RAGE,Receptor For Advanced Glycation End-Products Variant 20,Receptor For Advanced Glycation End-Products,RAGE Isoform NtRAGE-Delta,RAGE Isoform SRAGE-Delta,SCARJ1,Receptor for Advanced Glycation End Products,Advanced glycosylation end product-specific receptor
バックグランド
Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

RAGE 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
AzeliragonTTP-488; PF-4494700; PF-04494700Phase 3 ClinicalVtv Therapeutics
Alzheimer Disease; Brain metastases; Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Diabetic Nephropathies; Glioblastoma; Glioma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms
詳細
TRC-4186TX-41XX; TRC-4186Phase 2 ClinicalTorrent Pharmaceuticals Ltd
Diabetes Complications; Heart Failure
詳細
ARO-RAGEPhase 2 ClinicalArrowhead Pharmaceuticals Inc
Asthma
詳細